Develops first-in-class therapies for chronic kidney disease; lead candidate AP306 is a monotherapy, pan‑phosphate active transport inhibitor targeting hyperphosphatemia in CKD and dialysis patients. AP306 uniquely blocks active phosphate transport and showed significant serum phosphate reductions with favorable safety in Phase 2a; Phase 2b planned.